Skip to content 
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia. more
| Time Frame | RADX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -0.4% | 1.07% | 0.74% |
| 1-Month Return | -0.6% | 1.46% | 1.28% |
| 3-Month Return | 7.79% | 3.51% | 3.6% |
| 6-Month Return | -0.8% | 15.29% | 7.31% |
| 1-Year Return | 5.29% | 7.7% | 11.97% |
| 3-Year Return | -71.82% | 21.02% | 72.07% |
| Jun '22 | Jun '23 | Jun '24 | Jun '25 | |||
|---|---|---|---|---|---|---|
| Total Revenue | 8.83K | 292.36K | 299.23K | 3.63M | [{"date":"2022-06-30","value":0.24,"profit":true},{"date":"2023-06-30","value":8.05,"profit":true},{"date":"2024-06-30","value":8.24,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Cost of Revenue | - | - | - | 3.59M | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Gross Profit | 8.83K | 292.36K | 299.23K | 39.28K | [{"date":"2022-06-30","value":2.95,"profit":true},{"date":"2023-06-30","value":97.7,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":13.13,"profit":true}] | |
| Gross Margin | 100.00% | 100.00% | 100.00% | 1.08% | [{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":1.08,"profit":true}] | |
| Operating Expenses | 19.93M | 34.80M | 36.92M | 38.21M | [{"date":"2022-06-30","value":52.14,"profit":true},{"date":"2023-06-30","value":91.07,"profit":true},{"date":"2024-06-30","value":96.62,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Operating Income | (19.92M) | (34.51M) | (36.62M) | (38.17M) | [{"date":"2022-06-30","value":-1991635200,"profit":false},{"date":"2023-06-30","value":-3450808500,"profit":false},{"date":"2024-06-30","value":-3662085200,"profit":false},{"date":"2025-06-30","value":-3817386500,"profit":false}] | |
| Total Non-Operating Income/Expense | (19.73M) | (6.16K) | (11.82M) | 267.81K | [{"date":"2022-06-30","value":-7366.43,"profit":false},{"date":"2023-06-30","value":-2.3,"profit":false},{"date":"2024-06-30","value":-4415.2,"profit":false},{"date":"2025-06-30","value":100,"profit":true}] | |
| Pre-Tax Income | (30.29M) | (34.57M) | (47.85M) | (38.24M) | [{"date":"2022-06-30","value":-3029458200,"profit":false},{"date":"2023-06-30","value":-3457318900,"profit":false},{"date":"2024-06-30","value":-4785275500,"profit":false},{"date":"2025-06-30","value":-3823916500,"profit":false}] | |
| Income Taxes | 44.40K | 38.01K | 96.36K | 103.29K | [{"date":"2022-06-30","value":42.98,"profit":true},{"date":"2023-06-30","value":36.79,"profit":true},{"date":"2024-06-30","value":93.29,"profit":true},{"date":"2025-06-30","value":100,"profit":true}] | |
| Income After Taxes | (30.34M) | (34.61M) | (47.95M) | (38.34M) | [{"date":"2022-06-30","value":-3033897900,"profit":false},{"date":"2023-06-30","value":-3461119400,"profit":false},{"date":"2024-06-30","value":-4794911900,"profit":false},{"date":"2025-06-30","value":-3834245700,"profit":false}] | |
| Income From Continuous Operations | (30.34M) | (34.61M) | (47.95M) | (38.34M) | [{"date":"2022-06-30","value":-3033897900,"profit":false},{"date":"2023-06-30","value":-3461119400,"profit":false},{"date":"2024-06-30","value":-4794911900,"profit":false},{"date":"2025-06-30","value":-3834245700,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}] | |
| Net Income | (30.34M) | (34.61M) | (47.95M) | (38.34M) | [{"date":"2022-06-30","value":-3033897900,"profit":false},{"date":"2023-06-30","value":-3461119400,"profit":false},{"date":"2024-06-30","value":-4794911900,"profit":false},{"date":"2025-06-30","value":-3834245700,"profit":false}] | |
| EPS (Diluted) | - | - | - | (1.98) | [{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":-198,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| RADX | |
|---|---|
| Cash Ratio | 2.77 |
| Current Ratio | 3.37 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| RADX | |
|---|---|
| ROA (LTM) | -27.70% |
| ROE (LTM) | -109.20% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| RADX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.44 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| RADX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 3.02 |
| P/B | 1.21 |
| Price/FCF | NM |
| EV/R | 6.31 |
| EV/Ebitda | NM |
Radiopharm Theranostics Limited American Depositary Shares (RADX) share price today is $5.001
Yes, Indians can buy shares of Radiopharm Theranostics Limited American Depositary Shares (RADX) on Vested. To buy
Yes, you can purchase fractional shares of Radiopharm Theranostics Limited American Depositary Shares (RADX) via the Vested app. You can start investing in Radiopharm Theranostics Limited American Depositary Shares (RADX) with a minimum investment of $1.
You can invest in shares of Radiopharm Theranostics Limited American Depositary Shares (RADX) via Vested in three simple steps:
The 52-week high price of Radiopharm Theranostics Limited American Depositary Shares (RADX) is $10.63. The 52-week low price of Radiopharm Theranostics Limited American Depositary Shares (RADX) is $3.5.
The price-to-earnings (P/E) ratio of Radiopharm Theranostics Limited American Depositary Shares (RADX) is
The price-to-book (P/B) ratio of Radiopharm Theranostics Limited American Depositary Shares (RADX) is 1.21
The dividend yield of Radiopharm Theranostics Limited American Depositary Shares (RADX) is 0.00%
The market capitalization of Radiopharm Theranostics Limited American Depositary Shares (RADX) is $38.55M
The stock symbol (or ticker) of Radiopharm Theranostics Limited American Depositary Shares is RADX
Consider the share price of Radiopharm Theranostics Limited American Depositary Shares as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Radiopharm Theranostics Limited American Depositary Shares has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Radiopharm Theranostics Limited American Depositary Shares shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Radiopharm Theranostics Limited American Depositary Shares stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Radiopharm Theranostics Limited American Depositary Shares and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Radiopharm Theranostics Limited American Depositary Shares stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
